scale-up of the Company's rHuPH20 enzyme.
-- Selling, general and administrative expenses for the first quarter of
2008 were $4.2 million, compared with $2.0 million for the first
quarter of 2007, reflecting increases in compensation expenses
including share-based compensation expenses, as well as legal and
facilities expenses as compared with the prior-year quarter.
-- Cash and cash equivalents were $92.6 million as of March 31, 2008,
compared with $97.7 million as of December 31, 2007. During the
quarter the Company received a $3.5 million product-based payment for
Halozyme management will host a pipeline update conference call tomorrow to discuss these topics beginning at 8:00 a.m. PT (11:00 a.m. ET). To participate via telephone, please call 888-256-9044 for domestic callers, or 706-643-5585 for international callers. A telephone replay will be available for 48 hours by dialing 800-642-1687 for domestic callers, or 706-645-9291 for international callers. The reservation number is 44830661. The conference call will be broadcast live over the Internet at http://www.halozyme.com and the replay will be available on the Company's website for 30 days.
HYLENEX recombinant (hyaluronidase human injection) is indicated as an
adjuvant to increase the absorption and dispersion of other injected drugs,
as an adjuvant for subcutaneous fluid administration (hypodermoclysis), and
as an adjunct in subcutaneous urography for improving resorption of
radiopaque agents. Hyaluronidase is contraindicated in patients with
hypersensitivity to hyaluronidase enzyme or any other ingredients in the
formulation. Hyaluronidase should not be used to enhance the absorption and
dispersion of dopamine and/or alpha agonist drugs. Discontinue HYLENEX
recombinant if sensitizati
|SOURCE Halozyme Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved